Common biostructure of the colonic microbiota in neuroendocrine tumors and Crohn's disease and the effect of therapy

Inflammatory Bowel Diseases

Volumn 18, Issue 9, 2012, Pages 1663-1671

  Dörffel, Yvonne ^a   Swidsinski, Alexander ^a   Loening Baucke, Vera ^a   Wiedenmann, Bertram ^a   Pavel, Marianne ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

biostructure; colonic microbiota; Crohn's disease; neuroendocrine tumors

Indexed keywords

ALPHA2B INTERFERON; AZATHIOPRINE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; BACTEROIDES; BIFIDOBACTERIACEAE; BIOMASS; CANCER CHEMOTHERAPY; CHRONIC DIARRHEA; CLOSTRIDIUM; COLON FLORA; CONTROLLED STUDY; CROHN DISEASE; ENTEROBACTERIACEAE; FAECALIBACTERIUM PRAUSNITZII; FECES ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MIDGUT; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; ROSEBURIA; THERAPY EFFECT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; COLON; CROHN DISEASE; DIARRHEA; DNA, BACTERIAL; FECES; FEMALE; GRAM-POSITIVE BACTERIA; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; METAGENOME; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; YOUNG ADULT;

EID: 84864992687     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21923     Document Type: Article

References (41)

1. Klöppel G, Perren A, Heitz PU,. The gastropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014: 13-27.
2. Plöckinger U, Kloeppel G, Wiedenmann B, et al. The German NET-Registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology. 2009; 90: 349-363.
3. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006; 55: 205-211.
4. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12: 106-111.
5. Swidsinski A, Loening-Baucke V, Verstraelen H, et al. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008; 135: 568-579.
6. Swidsinski A, Loening-Baucke V, Vaneechoutte M, et al. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis. 2008; 14: 147-161.
7. Suau A, Rochet V, Sghir A, et al. Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Syst Appl Microbiol. 2001; 24: 139-145.
8. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in Colitis microbiota. Inflamm Bowel Dis. 2009; 15: 1183-1189.
9. Capella C, Heitz PU, Höfler H, et al. Revised classification of neuroendocrine tumors of lung, pancreas and gut. Virchows Archiv. 1995; 452: 547-560.
10. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444.
11. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984; 86: 249-266.
12. Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005; 43: 3380-3389.
13. Swidsinski A,. Standards for bacterial identification by fluorescence in situ hybridization within eukaryotic tissue using ribosomal rRNA-based probes. Inflamm Bowel Dis. 2006; 12: 824-826.
14. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105: 16731-16736.
15. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005; 12: 1083-1092.
16. Klimstra DS, Modlin IR, Adsay NV, et al. Pathologic reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathologic data set. Am J Surg Pathol. 2010; 34: 300-313.
17. Drozdov I, Kidd M, Gustafsson BI, et al. Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer. 2009; 115: 4934-4945.
18. Khan WI, Ghia JE,. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010; 161: 19-27.
19. Ng SC, Kamm MA, Stagg AJ, et al. Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation. Inflamm Bowel Dis. 2010; 16: 1787-1807.
20. Modlin IM, Gustafsson B, Moss SF, et al. Chromogranin A-biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol. 2010; 17: 2427-2443.
21. Sciola V, Massironi S, Conte D, et al. Plasma chromogranin A in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2009; 15: 867-871.
22. Helle KB, Corti A, Metz-Boutigue MH, et al. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci. 2007; 64: 2863-2886.
23. West NE, Wise PE, Herline AJ, et al. Carcinoid tumors are 15 times more common in patients with Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1129-1134.
24. Kortbeek J, Kelly JK, Preshaw RM,. Carcinoid tumors and inflammatory bowel disease. J Surg Oncol. 1992; 49: 122-126.
25. Le Marc'hadour F, Bost F, Peoc'h M, et al. Carcinoid tumour complicating inflammatory bowel disease. A study of two cases with review of the literature. Pathol Res Pract. 1994; 190: 1185-1192.
26. Brown GA, Kollin J, Rajan RK,. The coexistence of carcinoid tumor and Crohn's disease. J Clin Gastroenterol. 1986; 8: 286-289.
27. Doerffel Y, Pavel M, Loening-Baucke V, et al. Common biostructure of the fecal flora in celiac disease, Crohn's disease, and carcinoid tumors. Inflamm Bowel Dis. 2008; 14: 1613-1614.
28. Rinke A, Müller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009; 28: 4656-4663.
29. Christodoulou D, Skopelitou AS, Katsanos H, et al. Small bowel adenocarcinoma presenting as a first manifestation of Crohn's disease: report of a case, and a literature review. Eur J Gastroenterol Hepatol. 2002; 14: 805-810.
30. Ditschkowski M, Einsele H, Schwerdtfeger R, et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation. 2003; 75: 1745-1747.
31. Bruckner HW, Hrehorovich VR, Sawhney HS, et al. Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease. J Chemotherapy. 2006; 18: 545-548.
32. Matsuo K, Chi DS, Eno ML, et al. Vulvar mucinous adenocarcinoma associated with Crohn's disease: report of two cases. Gynecol Obstet Invest. 2009; 68: 276-278.
33. Scherzer TM, Staufer K, Novacek G, et al. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Aliment Pharmacol Ther. 2008; 28: 742-748.
34. Bargiggia S, Thorburn D, Anderloni A, et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther. 2005; 22: 209-215.
35. Kamoi S, Suzuki H, Yano Y, et al. Immunological studies on the patients with Crohn's disease and a new attempt of interferon treatment. Nippon Shokakibyo Gakkai Zasshi. 1989; 86: 193-199.
36. Debinski H, Forbes A, Kamm MA,. Low dose interferon gamma for refractory Crohn's disease. Ital J Gastroenterol Hepatol. 1997; 29: 403-406.
37. Ruther U, Nunnensiek C, Muller HA, et al. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Hepatogastroenterology. 1998; 45: 691-699.
38. Wirth HP, Zala G, Meyenberger C, et al. Alpha-interferon therapy in Crohn's disease: initial clinical results. Schweiz Med Wochenschr. 1993; 123: 1384-1388.
39. Colpaert S, Vastraelen K, Liu Z, et al. In vitro analysis of interferon gamma (IFN-gamma) and interleukin 12 (IL-12) production and their side effects in ileal Crohn's disease. Eur Cytokine Netw. 2002; 13: 431-437.
40. Rossi CP, Hanauer SB, Tomasevic R, et al. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009; 9: 22. DOI 10.1186/1471-230X-9-22.
41. Gasché C, Reinisch W, Vogelsang H, et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci. 1995; 40: 800-804.